3 – 5 NOVEMBER 2020
Delivered Digitally

VIEW THE AGENDA
9th ANNUAL
CELL LINE
DEVELOPMENT & ENGINEERING ASIA

VIEW THE AGENDA
10th ANNUAL
BIO MANUFACTURING

VIEW THE AGENDA
2nd ANNUAL
CELL & GENE THERAPY MANUFACTURING

Special Offer for China Pharmaceutical & Biotech Companies*

Knowledge Partners:

Brought to you by:

www.biopharmaproduction.com
Delivered digitally to help manage travel and physical distancing restrictions, the organising committee for 6th BDP China is delighted to present an innovative and creative format for the event.

Repurposed to address the emerging and likely permanent shifts in the Chinese biopharma industry, key leaders in the region will convene online to discuss investment climate beyond 2020, technological advancements, industry case studies, and partnerships and expansion opportunities across key value chains.

With live-streaming sessions, smart networking windows and elevated exhibition platforms at our virtual BDP China, join us as the industry convenes at this highly anticipated annual gathering of biopharma leaders.

**WHO WILL YOU MEET?**

**BY INDUSTRY:**
- China/MNC Pharma & Biotech .................................................. 50%
- CDMOs/CROs/CMOs ............................................................... 25%
- Tech Solution Providers ......................................................... 10%
- Regulators, Healthcare Agencies & Associations .................... 5%
- Scientific Research & Universities ....................................... 5%
- Others ....................................................................................... 5%

**BY GEOGRAPHY:**
- China ......................................................................................... 50%
- Japan, Korea, HK, Taiwan ...................................................... 15%
- Southeast Asia ........................................................................ 10%
- USA ............................................................................................ 10%
- Europe ......................................................................................... 10%
- Other Region ............................................................................ 5%

**OUR MARKETING AND DIGITAL MEDIA OUTREACH**
- 83000+ Unique Pageviews
- 76 Countries
- 34000+ LinkedIn Impressions

www.biopharmaproduction.com
## Day 1 of Main Conference | Tuesday, 3 November 2020

### KEYNOTE ADDRESS

**China’s Big Leap Towards BioPharma 2030 – Innovation, Industrialization, Internationalization**

### KEYNOTE ADDRESS

**China’s Biological Facilities for the Future – WuXi’s Story on Technology & Innovation**

#### 10th ANNUAL BIO MANUFACTURING

- Biomanufacturing 2030 – the hottest shifts in manufacturing in China
- Trends in Pharma 4.0 standards and China’s new drug delivery strategy
- Industry case studies for commercial manufacturing

#### 9th ANNUAL CELL LINE DEVELOPMENT & ENGINEERING ASIA

- The state-of-play for cell line development
- Applications for furthering biopharma R&D strategy
- Novel CLD platform technologies and tools
- Industry case studies for high-throughput screening and performance

#### 2nd ANNUAL CELL & GENE THERAPY MANUFACTURING

- Maneuvering the Chinese Market for Cell and Gene Therapies
- Addressing the next wave of innovations in cell therapies

## Day 2 of Main Conference | Wednesday, 4 November 2020

### Manufacturers’ Panel:

**New Therapies, New Tech & New Investments**

#### 10th ANNUAL BIO MANUFACTURING

- Smarty biomanufacturing and process optimization
- Manufacturing technology showcases – Improving cost and efficiency
- Innovative bioprocess development
- Sustainable manufacturing and scalability

#### 9th ANNUAL CELL LINE DEVELOPMENT & ENGINEERING ASIA

- Advancements in cell engineering techniques for complex proteins
- CRISPR and genomics in focus
- Data-driven, accelerated, and next-generation CLD
- Industry Panel: Perspectives on utilising platform technologies for CLD

#### 2nd ANNUAL CELL & GENE THERAPY MANUFACTURING

- Managing cost and accelerating manufacturing process
- Latest CAR T-cell technology developments
- Facilities design and construction for therapies

## Day 3 of Main Conference | Thursday, 5 November 2020

### KEYNOTE ADDRESS

**China’s Biopharma Capital Markets – Future Funds & Innovative Financing**

### Venture Capitals Roundtable: Show Me the Drug

#### 10th ANNUAL BIO MANUFACTURING

- DAL’s New GAMP and Licensing Law – Implementation and oversight
- QbD and Quality Matrix for meeting regulatory requirements
- Biomanufacturing process validation and quality risk management
- Best practices and strategies in biopharma supply chain integration

#### 9th ANNUAL CELL LINE DEVELOPMENT & ENGINEERING ASIA

- Optimising workflows and bioprocesses
- Exploring the synergies between engineered host cells and process development for commercial success
- Industry Panel: what’s next in the future of CLD&E

#### 2nd ANNUAL CELL & GENE THERAPY MANUFACTURING

- Investment and commercialisation landscape
- Case studies on clinical trial landscapes and efficacy evidence
<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Company/Institution</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Song Rulin</td>
<td>Executive President, China Pharmaceutical Innovation and Research Development Association (PhIRDA)</td>
<td>China</td>
<td></td>
</tr>
<tr>
<td>Li Jing Rong</td>
<td>Senior Vice President, Product Development and Manufacturing</td>
<td>Cstone Pharmaceuticals</td>
<td>China</td>
</tr>
<tr>
<td>Lynn Yang</td>
<td>Managing Director</td>
<td>Sequoia Capital</td>
<td>China</td>
</tr>
<tr>
<td>John Zhang</td>
<td>Vice President, Manufacturing Technology and Process Development</td>
<td>BellGene</td>
<td>China</td>
</tr>
<tr>
<td>Ma Yuan Hui</td>
<td>Executive Director, Preclinical Science</td>
<td>Shanghai Haikle Pharmaceutical</td>
<td>China</td>
</tr>
<tr>
<td>Glenn Hassan</td>
<td>Chief Finance Officer, Chief Business Officer</td>
<td>CANbridge Pharmaceuticals</td>
<td>China</td>
</tr>
<tr>
<td>Frank Ye</td>
<td>Senior Vice President, Technical Operations</td>
<td>Transcenda</td>
<td>China</td>
</tr>
<tr>
<td>Fu Wei</td>
<td>Chief Executive Officer</td>
<td>CBC Group</td>
<td>China</td>
</tr>
<tr>
<td>Dr. Chris Chen</td>
<td>Chief Executive Officer</td>
<td>WuXi Biologics</td>
<td>China</td>
</tr>
<tr>
<td>Dr. Orit Aharonovitz</td>
<td>Senior Director, CellLine &amp; Process Development</td>
<td>Teva Pharmaceuticals</td>
<td>Israel</td>
</tr>
<tr>
<td>Yin Nan Po</td>
<td>Director, Asia Supply Chain</td>
<td>Amgen</td>
<td>China</td>
</tr>
<tr>
<td>Dr. Kerstin Otte</td>
<td>Professor, Institute of Applied Biotechnology</td>
<td>Biberach University of Applied Sciences</td>
<td>Germany</td>
</tr>
<tr>
<td>Dr. Jill Cai</td>
<td>Vice President, Biologics Bioprocess and Development</td>
<td>WuXi Biologics</td>
<td>China</td>
</tr>
<tr>
<td>Wu You Ling</td>
<td>Chief Executive Officer</td>
<td>Zhejiang Teruisi Pharmaceuticals</td>
<td>China</td>
</tr>
<tr>
<td>Rani Jarkas</td>
<td>Chairman, Cedrus Investments</td>
<td>Hong Kong</td>
<td></td>
</tr>
<tr>
<td>Eric Chang</td>
<td>Head, Cell Line Development</td>
<td>Bell Biosci China</td>
<td></td>
</tr>
<tr>
<td>Dr. Jill Cai</td>
<td>Vice President, Biologics Bioprocess and Development</td>
<td>WuXi Biologics</td>
<td>China</td>
</tr>
<tr>
<td>Liu Xun</td>
<td>President, Biomedicine Development and Business Division</td>
<td>Jiangsu Hengrui Medicine</td>
<td>China</td>
</tr>
<tr>
<td>Lisa Zheng</td>
<td>Executive Director, Cell Line Development</td>
<td>Transcena</td>
<td>China</td>
</tr>
<tr>
<td>Dr. Zhu Jianwei</td>
<td>Professor and Director of MOE Engineering Research Center of Cell Engineering and Antibody</td>
<td>Shanghai Jiaotong University, CEO and Chief Scientist, Jecho Biopharmaceuticals, China</td>
<td>China</td>
</tr>
<tr>
<td>Yi Jizu</td>
<td>Senior Vice President, CMC &amp; Quality Operations</td>
<td>YZY Biopharma</td>
<td>China</td>
</tr>
<tr>
<td>Xi Chen</td>
<td>Director, Cell Engineering</td>
<td>Qbio Pharmaceuticals</td>
<td>China</td>
</tr>
<tr>
<td>David Shao</td>
<td>Chief Executive Officer</td>
<td>Yisheng Biopharma</td>
<td>China</td>
</tr>
<tr>
<td>Dr. Song Zhiwei</td>
<td>Principal Scientist</td>
<td>Bioprocessing Technology Institute</td>
<td>Singapore</td>
</tr>
<tr>
<td>Liu Dong Lian</td>
<td>Vice President, Manufacturing</td>
<td>TOT BIOPHARM</td>
<td>China</td>
</tr>
<tr>
<td>Dr. Karen Liu</td>
<td>Founding Partner</td>
<td>3E Bioventures Capital</td>
<td>China</td>
</tr>
<tr>
<td>Dr. Orit Aharonovitz</td>
<td>President, Head of CMC and Manufacturing</td>
<td>I-MAB Biopharma</td>
<td>China</td>
</tr>
<tr>
<td>Jerry Su</td>
<td>Chief Executive Officer</td>
<td>Zhejiang Huahai Biopharmaceuticals</td>
<td>China</td>
</tr>
<tr>
<td>Dr. Kerstin Otte</td>
<td>Professor, Institute of Applied Biotechnology</td>
<td>Biberach University of Applied Sciences</td>
<td>Germany</td>
</tr>
<tr>
<td>Yi Jizu</td>
<td>Senior Vice President, CMC &amp; Quality Operations</td>
<td>YZY Biopharma</td>
<td>China</td>
</tr>
<tr>
<td>Dr. Jill Cai</td>
<td>Vice President, Biologics Bioprocess and Development</td>
<td>WuXi Biologics</td>
<td>China</td>
</tr>
<tr>
<td>Dr. Pan Zhewei</td>
<td>Senior Director, Process Development</td>
<td>JundiPharma</td>
<td>China</td>
</tr>
<tr>
<td>Liang Tang</td>
<td>Vice President, CMC Management</td>
<td>WuXi Biologics</td>
<td>China</td>
</tr>
<tr>
<td>Dr. Song Zhiwei</td>
<td>Principal Scientist</td>
<td>Bioprocessing Technology Institute</td>
<td>Singapore</td>
</tr>
<tr>
<td>Frank Ye</td>
<td>Senior Vice President, Technical Operations</td>
<td>Transcena</td>
<td>China</td>
</tr>
<tr>
<td>Fu Wei</td>
<td>Chief Executive Officer</td>
<td>CBC Group</td>
<td>China</td>
</tr>
<tr>
<td>Eric Chang</td>
<td>Head, Cell Line Development</td>
<td>Bell Biosci China</td>
<td></td>
</tr>
<tr>
<td>Bao Cai</td>
<td>Senior Director, Manufacturing</td>
<td>Bio-Thera Solutions</td>
<td>China</td>
</tr>
<tr>
<td>Dr. Karen Liu</td>
<td>Founding Partner</td>
<td>3E Bioventures Capital</td>
<td>China</td>
</tr>
</tbody>
</table>
CONFERENCE AGENDA

DAY 1, TUESDAY 3 NOVEMBER 2020

13.00 Chairperson’s Opening Remarks

13.10 JOINT OPENING PLENARY
Joint Plenary Sessions with 10th Annual Biomanufacturing and 2nd Annual Cell & Gene Therapy Manufacturing

13.10 KEYNOTE ADDRESS
China’s Big Leap Towards BioPharma 2030 – Innovation, Industrialization, Internationalization
Dr. Song RuLin, Executive President, China Pharmaceutical Innovation and Research Development Association (PhIRDA), China

13.40 KEYNOTE ADDRESS
China’s Biological Facilities for the Future – WuXi’s Story on Technology and Innovation
Dr. Chris Chen, Chief Executive Officer, WuXi Biologics, China

14.10 Joint Plenary Sessions with 10th Annual Biomanufacturing and 11th Annual Biologics & Bioprocessing

14.30 NOVEL ADVANCES IN CLD TECHNIQUES & TECHNOLOGY

15.00 Enhancing Complex Protein Expression with Highly Efficient Gene Integration Technology
Senior Representative from Lonza

15.10 CRISPR in Cell Line Development: Applications of CRISPR in Rapid Development of Stable Transgene CHO Cell Lines
Dr. Zhu Jianwei, Professor and Director of MOE Engineering Research Center of Cell Engineering and Antibody, Shanghai Jiao Tong University; CEO and Chief Scientist, Jecho Biopharmaceuticals, China

16.00 Online Networking & Stretch Break

16.20 Advances in Single-Cell Genomics and RNA Sequencing Tools for Effective CLD Session Reserved for Namocell

16.50 Next-Generation Cell Line Engineering for Biopharmaceutical Production

18.30 End of Conference Day 1

DAY 2, WEDNESDAY 4 NOVEMBER 2020

13.00 Chairperson’s Opening Remarks

13.10 JOINT OPENING PLENARY
Joint Plenary Sessions with 10th Annual Biomanufacturing and 2nd Annual Cell & Gene Therapy Manufacturing

Panelists:
Jerry Su, Chief Executive Officer, Zhejiang Huahai Biopharmaceuticals, China
Glenn Hassan, Chief Finance Officer, Chief Business Officer, CANbridge Pharmaceuticals, China (tentatively confirming)
William Cao, Founder, Chairman & CEO, Gracell Biotechnologies Group, China

14.00 Online Networking & Stretch Break

14.10 9th Annual Cell Line Development & Engineering Asia Resumes

14.20 Chairperson’s Opening Remarks

14.30 ENGINEERING HOST CELL LINES, GENOMICS & CRISPR IN FOCUS

15.00 Enhancing Complex Protein Expression with Highly Efficient Gene Integration Technology
Senior Representative from Lonza

15.10 CRISPR in Cell Line Development: Applications of CRISPR in Rapid Development of Stable Transgene CHO Cell Lines
Dr. Zhu Jianwei, Professor and Director of MOE Engineering Research Center of Cell Engineering and Antibody, Shanghai Jiao Tong University; CEO and Chief Scientist, Jecho Biopharmaceuticals, China

16.00 Online Networking & Stretch Break

16.20 Advances in Single-Cell Genomics and RNA Sequencing Tools for Effective CLD Session Reserved for Namocell

16.50 Next-Generation Cell Line Engineering for Biopharmaceutical Production

18.20 End of Conference Day 2

DAY 3, THURSDAY 5 NOVEMBER 2020

13.00 Chairperson’s Opening Remarks

13.10 JOINT OPENING PLENARY
Joint Plenary Sessions with 10th Annual Biomanufacturing and 2nd Annual Cell & Gene Therapy Manufacturing

13.10 KEYNOTE ADDRESS
China’s Biopharma Capital Markets – Future Funds and Innovation
Fu Wei, Chief Executive Officer, CBC Group, China

13.40 Venture Capitals Roundtable: Show Me the Drug

Panelists:
Rani Iarkas, Chairman, Cedrus Investments; Hong Kong Judith Li, Partner, Lilly Asia Ventures, China
Dr. Karen Liu, Founding Partner, 3E Bioventures Capital, China
Lynn Yang, Managing Director, Sequoia Capital, China
Dr. John Zhu, Partner, 6 Dimensions Capital, China

14.00 Online Networking & Stretch Break

14.40 Panel Discussion: What’s Next in the Future of CLD & Biomanufacturing
Moderator:
Dr. Song Zhiwei, Principal Scientist, Bioprocessing Technology Institute, Singapore

Panelists:
Dr. Zhu Jianwei, Professor and Director of MOE Engineering Research Center of Cell Engineering and Antibody, Shanghai Jiao Tong University; CEO and Chief Scientist, Jecho Biopharmaceuticals, China
Dr. Kerstin Otte, Professor, Institute of Applied Biotechnology, Biberach University of Applied Sciences, Germany
Dr. Jerry Su, Chief Executive Officer, Zhejiang Huahai Biopharmaceuticals, China

15.00 Enabling New Frontiers in Recombinant Protein Therapeutic Development: A Novel and Modular CHO Expression Platform
Dr. Igor Fisch, Chief Executive Officer, Selexis, Switzerland

15.30 Integrated Cell Line Development Strategy in Whole CMC Picture
Xi Chen, Director, Cell Engineering, Qilu Pharmaceuticals, China

16.00 Accelerating CLD for Commercial Success
Dr. Pan Zhiwei, Senior Director, Process Development, Junshii Pharma, China

16.20 Online Networking & Stretch Break

16.40 Using CHO to Develop Biosimilars from Non-CHO Host Cell Line
Eric Chang, Head, Cell Line Development, JHL Biotech, China

17.00 A Fully Integrated Platform Approach for Highly-Quality CLD
Senior Representative from Shanghai Henlius Biotech, China

17.40 Panel Discussion: What’s Next in the Future of CLD & Biomanufacturing
Moderator:
Dr. Song Zhiwei, Principal Scientist, Bioprocessing Technology Institute, Singapore

Panelists:
Dr. Zhu Jianwei, Professor and Director of MOE Engineering Research Center of Cell Engineering and Antibody, Shanghai Jiao Tong University; CEO and Chief Scientist, Jecho Biopharmaceuticals, China
Dr. Kerstin Otte, Professor, Institute of Applied Biotechnology, Biberach University of Applied Sciences, Germany
Dr. Jerry Su, Chief Executive Officer, Zhejiang Huahai Biopharmaceuticals, China

18.20 End of Conference
CONFERENCE AGENDA

DAY 1, TUESDAY 3 NOVEMBER 2020

13.30 Opening Address: China’s Big Leap towards BioPharma 2030 – Innovation, Industrialization, Internationalization
Dr. Song Ru Lin, Executive President, China Pharmaceutical Innovation and Research Development Association (PHIRDA), China

13.50 Keynote Address: China’s Biologics Facilities for the Future – WuXi’s Story on Technology and Innovation
Dr. Chris Chen, Chief Executive Officer, WuXi Biologics, China

14.00 Online Networking & Stretch Break

BIOMANUFACTURING 2030 – CHINA’S GREAT LEAP

14.20 Trends in Pharma 4.0 Standards and China’s New Drug Delivery Strategy
Dr. Liu Xun, President, Biopharmaceutical Business Division, Jiansu Hengrui Medicine, China

14.50 Debottlenecking and Process Optimisation in China Biopharmaceutical Landscape
Dr. Simon Hsu, Senior Vice President, Technical Operations, Henlius, China

DAY 2, WEDNESDAY 4 NOVEMBER 2020


Confirmed Panelists:
Jerry Su, Chief Executive Officer, Zhejiang Huahai Biopharmaceuticals, China
Glenn Hassan, Chief Finance Officer, Chief Business Officer, CANbridge Pharmaceuticals, China (tentatively confirming)
William Cao, Founder, Chairman & CEO, Gracell Biotechnologies Group, China

14.00 Online Networking & Stretch Break

FUTURE FACILITIES & SMART BIOMANUFACTURING

14.20 Manufacturing Technology Showcases – Improving Cost and Efficiency
Frank Ye, Senior Vice President, Technical Operations, Transcenda, China

14.50 Manufacturing Technology – From Tech Transfer to Risk Analysis and Migration Strategy
Dr. John Zhang, Vice President, Manufacturing Technology and Process Development, BeiGene, China

15.20 Tech Transfer Development for mAb Manufacturing Productivity Optimization
Dr. Zack Zheng, Vice President, Process Development, JHL Biotech, China

15.50 Online Networking & Stretch Break

INNOVATIVE BIOPROCESS DEVELOPMENT

16.10 Glycosylation of Monoclonal Antibody and the Manipulation
Liu Dong Lian, Vice President, Manufacturing, CStone Pharmaceuticals, China

16.40 Vaccine Manufacturing Innovation
Dr. David Shao, President, Chief Executive Officer, Yisheng Biopharma, China

17.10 Case Study: Bio-Works’ 3rd Gen Agarose Resins to Purifying Antibody-based Therapies Using A Different 3-step Column Chromatography Approach
Dr. Bjorn Hammarberg, Business Development Asia, Bio-Works, Sweden

17.40 End of Conference Day 2

DAY 3, THURSDAY 5 NOVEMBER 2020

13.00 Keynote Address: China’s Biopharma Capital Markets – Future Funds and Innovative Financing
Fu Wei, Chief Executive Officer, CBC Group, China

13.30 Venture Capitalists’ Roundtable: Show Me the Drug
Moderator:
Fu Wei, Chief Executive Officer, CBC Group, China

Panelists:
Rani Jarkas, Chairman, Cedrus Investments, Hong Kong
Judith Li, Partner, Lilly Asia Ventures, China
Dr. Karen Liu, Founding Partner, J&J Bioventures Capital, China
Lynn Yang, Managing Director, Sequoia Capital, China
Dr. John Zhu, Partner, 6 Dimensions Capital, China

15.10 Impact of NMPA Reform on CMC Strategy at IND Stage
Dr. John Zeng, Vice President, Manufacturing, BeiGene, China

15.40 Integrated CMC Platforms to Develop Robust Downstream Process for Clinical Manufacturing
Dr. Zhang Zhe Ru, President, Head of CMC and Manufacturing, I-MAB Biopharma, China

16.10 Online Networking & Stretch Break

16.30 Ensure Uninterrupted Supply of Biological Drugs
Yin Nan Po, Director, Asia Supply Chain, Amgen, China

17.00 Biopharma Quality Assurance Best Practices and PAT Insights
Dr. Yi Jizu, Senior Vice President, CMC and Quality Operations, YZY Biopharma, China

17.30 Biomanufacturing Process Validation and Quality Risk Management
Bao Cai, Senior Director, Manufacturing, Bio-Thera Solutions, China

18.00 End of Conference Day 3

www.biopharmaproduction.com
## DAY 1, TUESDAY 3 NOVEMBER 2020

13:00 Opening Address: China’s Big Leap towards BioPharma 2030 — Innovation, Industrialization, Internationalization  
Dr. Song Ru Lin, President, China Pharmaceutical Innovation and Development Association (PhIRDA), China

13:30 Keynote Address: China’s Biologics Facilities for the Future — WuXi’s Story  
Dr. Chris Chen, Chief Executive Officer, WuXi Biologics, China

14:00 Online Networking & Stretch Break

### CHINA MARKET

14:20 Chairperson’s Opening Remarks

14:30 Next Generation Cellular Gene Therapeutics  
Dr. William Cao, Founder, Chairman and CEO, Gracel Biotechnologies Group, China

15:00 C-Suite Industry Panel: Regulatory Pathways for Cell and Gene Therapies in the Region, and China  
Panelists: Richard Wang, Chief Executive Officer, Fosun Kite Biotechnology, China

18:10 Chairperson’s Summary and End of Day 1

### TECHNOLOGY AND INNOVATION

15:45 Dr. Zhang Yu, Senior Vice President and Chief Scientific Officer, Vaccinio Cell&Gene Engineering, China  
James Li, Co-Founder and Chief Executive Officer, JW Therapeutics, China  
Liu Yaron, Chief Executive Officer, Grit Therapeutics, China

16:10 Finding the Market Growth in China  
Richard Wang, CEO, Fosun Kite Biotechnology, China

16:40 Commercial Launch of CAR-T Therapy in China  
Liu Yaron, Chief Executive Officer, Grit Therapeutics, China

17:10 Case Study: Tumor-Infiltrating Lymphocyte Development  
Liu Yaron, Chief Executive Officer, Grit Therapeutics, China

17:40 The Case of Solid Tumors: From Liquid to Solid Tumors, from Manual to Automatic Manufacturing  
Dr. Zhang Yu, Senior Vice President and Chief Scientific Officer, Vaccinio Cell&Gene Engineering, China

18:10 Chairperson’s Summary and End of Day 1

### INVESTMENTS AND COMMERCIALISATION

16:00 Online Networking & Stretch Break

16:30 Accelerating CAR-T Development and Manufacturing  
Yao Shuyuan, General Manager, WuXi AppTec, China

17:15 The Future of Stem Cells Therapy and Technology Trends  
Pawan Gupta, Vice President, Medical Affairs, Stempeutics, India

17:45 Swedish initiatives for Building CAR-T and ATMP Ecosystem  
Ase Rosenqvist, Nordic CAR T Operational Lead, Cell Therapy, Bristol Myers Squibb, Sweden

### Online Networking & Stretch Break

18:15 Case Study: Placenta Cell-Based Gene Therapy on Blood Diseases  
Lior Raviv, Vice President Development, Pluristem Therapeutics, Israel

18:45 Indonesia Case Study: Developing UC Stem Cells for COVID-19  
Sandy Qlintang, Deputy Director, PT Kalbe, Indonesia

19:15 Chairperson’s Summary and End of Day 2

## DAY 2, WEDNESDAY 4 NOVEMBER 2020

13:00 Keynote Address: China’s Biopharma Capital Markets — Future Funds and Innovative Financing  
Fu Wei, Chief Executive Officer, CBC Group, China

13:30 Venture Capital's Roundtable: Show me the Drug  
Moderator: Fu Wei, Chief Executive Officer, CBC Group, China

Panelists: Jerry Su, Chief Executive Officer, Zhejiang Huahai Biopharmaceuticals, China  
Glenn Hassan, Chief Finance Officer, Chief Business Officer, CANbridge Pharmaceuticals, China (tentatively confirming)  
William Cao, Founder, Chairman & CEO, Gracel Biotechnologies Group, China  
More panelists to be confirmed

14:00 Online Networking & Stretch Break

### TECHNOLOGY AND INNOVATION

14:20 Cell and Gene R&D Strategy Showcase — A Case Study of Epigeneron  
Hara Ryajiro, Head of R&D Strategy, Epigeneron, Inc., Japan

15:00 Innovations in CAR T-Cell Technology Developments and Manufacturing  
For speaking enquiry, please contact Yvonne.Leong@informa.com

15:30 Technical Showcase: Solid Tumors Treatment with TCR-T Generation  
Alex Liu, TCR Discovery and Early Development, Cytovant Sciences, China

16:00 Online Networking & Stretch Break

16:30 Biotech Investors’ Roundtable: Financial Incentives, Investments and Pricing  
Panelists: Kan Chen, Principal, Qiming Weichuang Venture Capital Management, China  
Paolo Morgese, Director for EU Market Access and Member Relations, Alliance for Regenerative Medicine, Switzerland

17:10 Chairperson’s Summary and End of Day 3

## DAY 3, THURSDAY 5 NOVEMBER 2020

13:00 Keynote Address: China’s Biopharma Capital Markets — Future Funds and Innovative Financing  
Fu Wei, Chief Executive Officer, CBC Group, China

13:30 Venture Capital's Roundtable: Show me the Drug  
Moderator: Fu Wei, Chief Executive Officer, CBC Group, China

Panelists: Jerry Su, Chief Executive Officer, Zhejiang Huahai Biopharmaceuticals, China  
Glenn Hassan, Chief Finance Officer, Chief Business Officer, CANbridge Pharmaceuticals, China (tentatively confirming)  
William Cao, Founder, Chairman & CEO, Gracel Biotechnologies Group, China  
More panelists to be confirmed

14:00 Online Networking & Stretch Break

16:00 Online Networking & Stretch Break

16:30 Accelerating CAR-T Development and Manufacturing  
Yao Shuyuan, General Manager, WuXi AppTec, China

17:15 The Future of Stem Cells Therapy and Technology Trends  
Pawan Gupta, Vice President, Medical Affairs, Stempeutics, India

17:45 Swedish initiatives for Building CAR-T and ATMP Ecosystem  
Ase Rosenqvist, Nordic CAR T Operational Lead, Cell Therapy, Bristol Myers Squibb, Sweden

18:15 Case Study: Placenta Cell-Based Gene Therapy on Blood Diseases  
Lior Raviv, Vice President Development, Pluristem Therapeutics, Israel

18:45 Indonesia Case Study: Developing UC Stem Cells for COVID-19  
Sandy Qlintang, Deputy Director, PT Kalbe, Indonesia

19:15 Chairperson’s Summary and End of Day 2

www.biopharmaproduction.com
Unrivalled Opportunity to Profile your Company

Thought leadership
Offer keynotes and educational sessions to your audience through live webinars or pre-recorded video broadcast with automated reminders, Q&A sessions and polls to keep your attendees engaged.

Informa Data+
Unique option for increased lead generation through retargeting of our global proprietary database in social media.

Powerful Digital Matchmaking
Build valuable relationships with our intelligent matchmaking tool, live chat and integrated 1:1 video calls.

Virtual Booths
Online spaces with your brand identity, showcase your product demos, live chat with audiences. Manage your own logo, description video, collateral, staff profiles and more.

Focused Metrics
Measurable exposure and trackable meetings generate great ROI. Booth views, meeting requests, engagement rates – you’ll have all the data you need.

Accelerated Brand Exposure
Gain prominence with focused digital theatres in the lead up, main conference days, and up to 3 months after the event with our on-demand content modules.

For more information on digital sponsorship opportunities, please contact: Yvonne Leong, +65 9852 3283, Yvonne.Leong@informa.com

www.biopharmaproduction.com
**International Companies – Outside China**  
*International Companies with Global HQ Located Outside China*

<table>
<thead>
<tr>
<th></th>
<th>Early Bird Rate</th>
<th>Normal Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Register &amp; pay before 11 September 2020</td>
<td>Register &amp; pay after 11 September 2020</td>
</tr>
<tr>
<td><strong>Individual Rate</strong></td>
<td>USD 595</td>
<td>USD 695</td>
</tr>
<tr>
<td><strong>Group Rates (Price per Delegate)</strong></td>
<td><strong>5 or More</strong></td>
<td><strong>10 or More</strong></td>
</tr>
<tr>
<td><strong>5 or More</strong></td>
<td>USD 495</td>
<td>USD 495</td>
</tr>
<tr>
<td><strong>10 or More</strong></td>
<td>USD 395</td>
<td>USD 495</td>
</tr>
</tbody>
</table>

**Local China Companies**

<table>
<thead>
<tr>
<th></th>
<th>Early Bird Rate</th>
<th>Normal Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Register &amp; pay before 11 September 2020</td>
<td>Register &amp; pay after 11 September 2020</td>
</tr>
<tr>
<td><strong>Individual Rate</strong></td>
<td>USD 895</td>
<td>USD 995</td>
</tr>
<tr>
<td><strong>Group Rates (Price per Delegate)</strong></td>
<td><strong>5 or More</strong></td>
<td><strong>10 or More</strong></td>
</tr>
<tr>
<td><strong>5 or More</strong></td>
<td>USD 795</td>
<td>USD 895</td>
</tr>
<tr>
<td><strong>10 or More</strong></td>
<td>USD 695</td>
<td>USD 795</td>
</tr>
</tbody>
</table>

**3 EASY WAYS TO REGISTER**

**Contact Miki Kong**  
+65 6508 2477

**Registration Enquiry Email**  
info.sg@informa.com

**Website**  
www.biopharmaproduction.com

**Register Now**

Delegates who have successfully registered for the event will receive their Online Networking System (ONS) details to connect and network with other attendees nearer to the event date!

*Organisers reserved rights to accept/reject complimentary pass applications submitted, also to request specific job functions as described below. This is to ensure you gain maximum benefit from conference content and networking activities.*

**Brought to you by:**
[Informa Connect](www.biopharmaproduction.com)